Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                

BST - AB3 - T2 20 - Group Report

Download as docx, pdf, or txt
Download as docx, pdf, or txt
You are on page 1of 13

1

Business Strategy: Group Report

Date: -

Submitted to: -

Submitted by: -
2

Table of Contents
1 Introduction:.............................................................................................................................4

2 History and Growth:.................................................................................................................4

2.1 Supply:..............................................................................................................................4

2.2 Guidelines, Codes, & Values:...........................................................................................5

3 Provision of Services:...............................................................................................................5

3.1 Prescribed Medicines and Vaccines:.................................................................................5

3.2 Consumer Healthcare:.......................................................................................................6

3.3 ViiV Healthcare:...............................................................................................................6

4 Structure & Critical Success:...................................................................................................6

4.1 Corporate memory:...........................................................................................................7

4.2 Creativity:..........................................................................................................................7

4.3 Cross-Functional Alignment:............................................................................................7

5 Vision, Mission, & Corporate Strategy:...................................................................................7

5.1 Flexibility:.........................................................................................................................8

5.2 Responsible attitude:.........................................................................................................8

5.3 Pollution Incident Retort Proposal:...................................................................................8

6 Business Strategy:....................................................................................................................8

6.1 Richer Information in Experimental Trials:......................................................................9

7 Functional Strategy:.................................................................................................................9
3

7.1 Open Innovation:.............................................................................................................10

8 Issues and Problems:..............................................................................................................10

8.1 Covid-19:........................................................................................................................10

9 Recommendations:.................................................................................................................11

10 Conclusion:.............................................................................................................................11

11 References..............................................................................................................................12
4

1 Introduction:

The report under discussion illustrates a pharmaceutical industry of Australia. The

background history, progress and services provisioned by the organization are illustrated as

under. It comprises of the structure of the company and the factors that are responsible for its

success. The business strategy opted by GSK and the future aim of the industry. It also comprises

of the steps taken by GSK during the covid-19 pandemic and the issues it has been facing during

the outbreak. The suggestions that should be improvised by GSK in order to overcome and

mitigate the issues and challenges during the pandemic are also demonstrated as under.

2 History and Growth:

GSK stand for GlaxoSmithKline Australia Pty Ltd. It was discovered in 1886. It is a

science-led pharmaceutical industry that aims to provide people with the assistance of medical

and health care [ CITATION Com19 \l 1033 ]. There are a total of seventy-two further industries

of GSK located in Australia, comprising of 254-300 employees in each company of Australia.

The GSK health consumers have been producing $313.32 sales from each consumer healthcare

center. The GSK business is strong and stable enough in Australia and has been generating $850

million revenue in 2018. The industry has been providing people with all the medical services

and product through the global business tactical approaches, in order to treat people with latest

technology.

2.1 Supply:

GSK has been supplying its products to New South Whales and has been increasing the

sales up to $345 million each year, starting form 2018. There are about fifteen thousand

employees who are related to the manufacturing of medicine or products the community with
5

medical products and equipment’s, the industry aims to provide assistance through their

technology and knowledge, to every single member of this field, within or across the globe. The

organization has been takin tactical approaches, in order to expand the business on an

international scale, providing the atmosphere and environmental bodies with high quality

products of health care.

2.2 Guidelines, Codes, & Values:

The code of conduct followed by the employees of GSK are derived from the Medicines

Australian Code of Conduct as well as Australian Self-Medication Industry Standards. The

global policies of the industry comprise of all the basic law and legislature relating to the

whistleblowing, privacy, security, media and procurement policies. It also involves the

corruption programs.

3 Provision of Services:

GSK assists in the provision of a variety of diversified products [ CITATION Epp20 \l 1033 ].

The medicines, healthcare necessities and vaccines are prescribed.

3.1 Prescribed Medicines and Vaccines:

Prescribed Medicines and vaccines involve all sorts of significant information, for

instance, the product and consumer medicine information are involved in it. The health care

professionals are responsible for the provision of correct information of the product. The

company guarantees to provide all the information related to the product in order to address the

side effects and benefits of the the medicine that is prescribed by their company. The consumer

medicine information is disclosed to those people only who are the customers of the prescribed

medicines.
6

3.2 Consumer Healthcare:

The consumer healthcare business generates and sales the products necessary for the

consumer's or customer's oral health, Skin health varieties, respiratory disorders, and nutritional

categories. It is one of the leading industries all over the world. In 2019, on the 1st of August

GSK confirmed their transactions with Pfizer. This aim of this approach was to expand the

business of consumer health care into Consumer Healthcare Joint Venture.

3.3 ViiV Healthcare:

GSK provides the people and customers with all the service related to the treatment and

cure of HIV. In Australia, the treatment of HIV has been performed for a very log, in order to

expand the business as large as possible to equip and treat the patients facing HIV on a global

scale. GSK is hundred percent involved in order to treat the issues of HIV as well as AIDS and

expand the interest in regard to this sector of the industry.

4 Structure & Critical Success:

GSK is responsible for several different operations and activities of the

organization[ CITATION Fer201 \l 1033 ]. Commercial successfulness has been leading the

organization to operate in a manner that can be effective enough for the community as well as

the industry. The industry aims to develop sustainable financial returns for their own benefits. the

structure of GSK is based on its innovation and creative or new ides that keep on developing and

enhancing every year these aspects make GSK different and productive enough from any other

pharmaceutical industry. The factors responsible for the critical success of GSK are illustrated as

follows.
7

4.1 Corporate memory:

A long-term approach is necessary instead of choosing a short-term management

approaches. A stiff and firm foundation is supposed to be set, that has been leading GSK as well

to success.

4.2 Creativity:

GSK has been showing creativity in order to resolve the internal a well as external issues

and challenges. For instance, the Reconciliation Action Plan devised by GSK is a significant

innovative step towards success.

4.3 Cross-Functional Alignment:

Cross-functional alignment of all the internal and external operations and activities of the

industry has led GS to lead in the race of success. The inputs have been derived form different

industries to support GSK, for instance, the collaboration with Monash University.

5 Vision, Mission, & Corporate Strategy:

GSK has been aligned in a global tactical approach to achieve the mission of the industry.

The mission of GSK is to deliver all the latest and effective medications as well as medical

services to all the diseases, in the most innovative manner[ CITATION GLA19 \l 1033 ]. GSK

aims to work and develop innovative strategies for the expansion of the business.

The vision of GSK is to lay out several different foundations and programs that can be

effective and prove to be very favorable for the industry in the long-run. For instance, the

Corporate Responsibility Committee of GSK makes sure that the approach that has been

improvised by the industry is based on corporate responsibility is as appropriate for the industry.
8

5.1 Flexibility:

GSK assists to provide health safety to people on a broader scale, it is not restricted to a

single community. Health benefits are delivered through a flexible and innovative approaches

that can provide assistance on an international scale.

5.2 Responsible attitude:

A responsible and authorized environment is developed and delivered to the consumers

because it is about the health and care of the customer. The values and ethics are followed in

order to place the patients as the first responsibility of GSK.

5.3 Pollution Incident Retort Proposal:

PIRMP states as Pollution Incident Response Management Plan, holding the

Environmental Protection Authority License, aims to protect and secure the environment form all

the effluents. The GSK emergency centers will be dealing with any sort of environmental threats

and risks.

6 Business Strategy:

There are several different factors that can lead to the success of pharmaceutical

industries for instance GSK is a pharmaceutical industry that has been leading in the front face

for many years due to its Technology based tactical approaches and operational marketing is one

of the main factors that has leading it to success. Moreover, outsourcing is also one of the main

practical approach that can assist pharmaceutical companies and has assisted GSK in the

management of a good business. the industry has been investing in technology for many years in

order to develop medications and medical healthcare supplies that can treat patients for several

different diseases [ CITATION GSK16 \l 1033 ]. The business strategy also involves a detailing
9

where consumers can receive direct and direct response from the customers and the consumers

they are dealing with.

6.1 Richer Information in Experimental Trials:

GSK has been carrying out several different clinical trials in order to gain maximum

information through the partnership approaches. It has been observed that partnership has

assisted GSK to enhance in capturing the information. the activities and feedback of the patients

as well as the consumers have been monitored continuously, in order to mitigate and carry out all

the decisions that can equip in the formation of advanced and new medication[ CITATION

Smi20 \l 1033 ]. Biosensors and other mobile instruments have been used to monitor all the

activities as well as track the clinical experimentation that have been carrying out on the patients.

these devices have been able to record and track all the information and activities of the patients

even in their sleep by creating least amount of introduction and any barriers in the daily life of

the patient.

7 Functional Strategy:

there are several different tactical approaches that should be followed by pharmaceutical

industries. The first one involves to reorganize the operational prices as been carried out by GSK

in Australia, this type of tactical approach will assist their industry to limit the staff and

workforce performing all the corporate tactical approaches of the pharmaceutical industry. The

functional sector of the industry has its own responsibility and set of duties it has to perform

organized separately in order to avoid any sort of mismanagement of the workforce. The

functions of the industry can lead to success if experienced employees and workers are hired

instead of fresh employees because the experience employees tend to have more skilled and

effective techniques.
10

7.1 Open Innovation:

Functional strategies of GSK involve the open innovation as well as the expansion of

resources on FIR global scale. Research has been carried out by different scientific communities

of Australia that aims to develop innovative and practical approaches for the mitigation of

several kinds of diseases that have been test my patience all over the world, for instance Malaria

Tuberculosis and other infections. The open innovation program of Australia has also been New

Zealand. GSK has also been funding different markets that have been developing scientific tools

and health care products for the patients [ CITATION Kwo20 \l 1033 ]. Open innovation is

basically defined as the execution of creative ideas with the collaboration of other countries such

as Australia and New Zealand.

8 Issues and Problems:

There are several different challenges and issues that have been faced by GSK during the

outbreak of coronavirus. The outbreak has led to the shortage of medical equipment as well as

enough space to provide medications to the patients who are going through the disease. It has

also been observed that the sales of GSK has been reduced to 6.65 billion pounds, as the main

business of GSK is based on vaccines medications and pharmaceuticals that have been reduced

to 80% of its total calculated sales.

8.1 Covid-19:

GSK has been carrying out research and several activities to get back on track for its

medicine and vaccine production[ CITATION GSK20 \l 1033 ]. GSK has been collaborating

with several different industries and companies who can assist them in the production of a
11

vaccine for coronavirus. The pandemic has led the industry to a very dreadful state. The

employees are needed to be protected from the outbreak.

9 Recommendations:

GSK has taken the responsibility of its planet and its people[ CITATION Pat20 \l 1033 ].

GSK has been carrying out several different programs and campaigns that can assist in the

development of innovative and creative healthcare services.

 GSK is supposed to capitalize on the skills and expertise of different individuals and

utilize them for the mitigations of challenges and several different issues.

 GSK has made alliance with Sanofi in order to collaborate in order to cure covid-19.

 Moreover, Clover and GSK are also interlinked in order to cure the virus.

 A Canadian biopharmaceutical industry was established on the foundation of GSK for the

devilment of a vaccine that can cure Covid-19.

10 Conclusion:

Thus, in conclusion it can be illustrated that GSK is one of the leading pharmaceutical

industries that has been expanded on a global scale. The headquarters of GSK is located in UK

that is dealing with all the retailers across the globe. GSK has encountered several different

challenges and issues due to Covid-19 and has taken different improvement steps in terms of the

expansion of the industry as well as to figure out the cure or vaccine for Covid-19.
12

11 References

C., S., 2020. BUSINESS PLANNING PRACTICES WITH REFERENCE

PHARMACEUTICAL INDUSTRY PUNE DISTRICT. Studies in Indian Place Names , 40(27),

pp. 1180-1192.

Company Type: Proprietary Company, 2019. GlaxoSmithKline Holdings Pty Ltd - Premium

Company Report Australia. [Online]

Available at: https://www.ibisworld.com/au/company/glaxosmithkline-holdings-pty-ltd/8961/

[Accessed 27 August 2020].

E., F. & Meñez, N., 2020. Asia Pacific Journal of Academic Research in Social Sciences.

Success Factors of Franchising Retail Pharmaceutical Companies: A Proposed Action Plan for

Entrepreneurs, 6(1), pp. 19-39.

GLAXOSMITHKLINE CONSUMER HEALTHCARE AUSTRALIA PTY LTD, 2019.

GLAXOSMITHKLINE CONSUMER HEALTHCARE AUSTRALIA PTY LTD. [Online]

Available at: https://www.dnb.com/business-directory/company-

profiles.glaxosmithkline_consumer_healthcare_australia_pty_ltd.317a076cd81ba6c470d8b7f7fa

3ea12f.html#industry-info

[Accessed 2020 August 2020].

Greg, P., 2020. Medication adherence in diseases requiring specialty medications: a pharmacist's

perspective on the impact of the World Health Organization's categorizations, along with

technology and pharmaceutical industry-initiated financial assistance. University of Liverpool,

2(01), pp. 19-20.


13

GSK Australia, 2016. Responsible Business. [Online]

Available at: https://au.gsk.com/media/388915/gska_responsible_business_report_2016.pdf

[Accessed 27 08 2020].

GSK Australia, 2020. GSK's response to the COVID-19 pandemic. [Online]

Available at: https://au.gsk.com/en-au/media/gsks-response-to-covid-19-pandemic/

[Accessed 27 08 2020].

Jinhee, K., Kim, C. & Lee, K., 2020. Moderating Effect of the Continental Factor on the

Business Strategy and M&A Performance in the Pharmaceutical Industry for Sustainable

International Business. Sustainability, 12(12), pp. 49-85.

Joanne, E., Parkinson, B. & Hawse, S., 2020. Health System Sustainability: The Pharmaceutical

Benefits Scheme in Australia. In Industry and Higher Education, 01(12), pp. 13-44.

You might also like